Edwards Lifesciences Co. (NYSE:EW) Short Interest Update

Edwards Lifesciences Co. (NYSE:EWGet Rating) saw a significant drop in short interest in the month of April. As of April 30th, there was short interest totalling 4,860,000 shares, a drop of 15.2% from the April 15th total of 5,730,000 shares. Currently, 0.8% of the shares of the company are short sold. Based on an average daily volume of 2,740,000 shares, the days-to-cover ratio is presently 1.8 days.

Several research firms have issued reports on EW. Truist Financial began coverage on shares of Edwards Lifesciences in a research report on Tuesday, April 12th. They issued a “buy” rating and a $145.00 price target on the stock. StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, May 5th. Raymond James cut their price objective on Edwards Lifesciences from $134.00 to $126.00 and set an “outperform” rating on the stock in a research note on Thursday, January 27th. Stifel Nicolaus decreased their price target on shares of Edwards Lifesciences from $132.00 to $120.00 and set a “buy” rating for the company in a report on Thursday, January 27th. Finally, Evercore ISI reduced their price objective on Edwards Lifesciences from $130.00 to $122.00 and set an “outperform” rating for the company in a research report on Thursday, January 27th. Five equities research analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of “Buy” and an average price target of $127.50.

NYSE:EW opened at $97.39 on Wednesday. Edwards Lifesciences has a 12-month low of $88.96 and a 12-month high of $131.73. The firm has a market capitalization of $60.55 billion, a price-to-earnings ratio of 39.91, a P/E/G ratio of 2.95 and a beta of 1.16. The stock’s 50 day moving average price is $111.77 and its two-hundred day moving average price is $114.24. The company has a quick ratio of 2.64, a current ratio of 3.41 and a debt-to-equity ratio of 0.10.

Edwards Lifesciences (NYSE:EWGet Rating) last posted its earnings results on Tuesday, April 26th. The medical research company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.02. Edwards Lifesciences had a return on equity of 25.80% and a net margin of 28.72%. The business had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same period in the previous year, the firm earned $0.54 EPS. The firm’s revenue was up 10.2% compared to the same quarter last year. Equities research analysts expect that Edwards Lifesciences will post 2.56 EPS for the current year.

In related news, VP Huimin Wang sold 3,675 shares of the firm’s stock in a transaction that occurred on Tuesday, March 8th. The shares were sold at an average price of $107.60, for a total transaction of $395,430.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Catherine M. Szyman sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, February 18th. The shares were sold at an average price of $106.31, for a total transaction of $2,126,200.00. The disclosure for this sale can be found here. Insiders sold 250,031 shares of company stock worth $26,973,194 in the last 90 days. 1.29% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. American National Bank increased its stake in Edwards Lifesciences by 99.1% in the first quarter. American National Bank now owns 233 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 116 shares during the last quarter. Core Alternative Capital grew its holdings in Edwards Lifesciences by 513.2% during the 1st quarter. Core Alternative Capital now owns 233 shares of the medical research company’s stock worth $27,000 after acquiring an additional 195 shares during the last quarter. Liberty Wealth Management LLC increased its holdings in Edwards Lifesciences by 362.3% in the third quarter. Liberty Wealth Management LLC now owns 245 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 192 shares during the period. EverSource Wealth Advisors LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter worth about $29,000. Finally, Rinkey Investments acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $29,000. Institutional investors and hedge funds own 82.54% of the company’s stock.

About Edwards Lifesciences (Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Featured Articles

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.